Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 26

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 26
---
     |                  |   -125.0 |                           |
| Other core operating profit adjustments                                              |     |                  |     -2.0 |            |     |                  |        — |                           |
| Finance income and (expenses), net                                                   |     |                  |   -163.5 |            |     |                  |   -167.0 |                           |
| Adjusted free cash flow*1                                                            |     |                  |    769.0 |            |     | 750.0 - 850.0    |          |                           |
| Capital expenditures (cash flow base)                                                |     |                  |   -347.8 |            |     | -270.0 - 320.0   |          |                           |
| Depreciation and amortization (excluding intangible assets associated with products) |     |                  |   -213.2 |            |     |                  |   -216.0 |                           |
| Cash tax rate on adjusted EBITDA (excluding divestitures)*1                          |     |                  |          | Approx.10% |     |                  |          |                 Mid teen% |

*2 Includes in-process R&D.

*3 Includes restructuring expense primarily related to the enterprise-wide efficiency program of JPY 128.1 billion in FY2024 actual results and JPY 48.0 billion in FY2025 forecast.

### Management Guidance
Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance.

|                       |     | FY2025 Management Guidance 
 CER % Change*1             |
| Core revenue          |     | Broadly Flat               |
| Core operating profit |     | Broadly Flat               |
| Core EPS              |     | Broadly Flat               |

Other assumptions used in preparing the FY2025 Forecast and the Management Guidance

• The FY2025 forecast and the management guidance do not reflect the potential impact of tariffs being introduced on pharmaceutical products by the U.S. administration, nor the potential impact of tariffs introduced by other countries in response to U.S. tariffs.

• The FY2025 forecast and the management guidance assume global VYVANSE sales of JPY 241.0 billion, a year-on-year decline of JPY 109.6 billion (30% decline at CER).

#### Forward looking statements
All forecasts in this document are based on information currently available to management, and do not represent a promise or guarantee to achieve these